ReviewPediatric nephrology (Berlin, Germany)2007
Therapeutic approach to FSGS in children.
Review in Pediatric nephrology (Berlin, Germany), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.Kidney international · 2011Trial
- Development of the Nephrotic Syndrome Symptom and Impact Patient Reported Outcome (NephroSSI-PRO) measure for use in adults and adolescents with primary glomerulopathies.Journal of patient-reported outcomes · 2025Article
- Abatacept Decreases Renal T-cell Infiltration and Renal Inflammation and Ameliorates Progressive Renal Injury in Obese Dahl Salt-sensitive Rats Before Puberty.Journal of cardiovascular pharmacology · 2024Article
- Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Primary focal segmental glomerulosclerosis in children: epidemiology, clinical presentation and prognosis.La Tunisie medicale · 2023Article
- Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design.Kidney international reports · 2021Article
- Focal segmental glomerulosclerosis in children complicated by posterior reversible encephalopathy syndrome.The Journal of international medical research · 2018Article
- Glomerular nestin expression: possible predictor of outcome of focal segmental glomerulosclerosis in children.Pediatric nephrology (Berlin, Germany) · 2015Article
- Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium.Pediatric nephrology (Berlin, Germany) · 2013Observational
- NGAL distinguishes steroid sensitivity in idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2012Article
- Discovery and initial validation of α 1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome.Proteomics. Clinical applications · 2011Article
- Treatment of steroid and cyclosporine-resistant idiopathic nephrotic syndrome in children.International journal of nephrology · 2011Article
- C1q nephropathy in the pediatric population: pathology and pathogenesis.Pediatric nephrology (Berlin, Germany) · 2010Review
- Article
- Rituximab for refractory focal segmental glomerulosclerosis.Pediatric nephrology (Berlin, Germany) · 2008Article
- Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.Paediatric drugs · 2008Review
- Educational feature on focal segmental glomerulosclerosis (FSGS): an introduction.Pediatric nephrology (Berlin, Germany) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Therapy of primary focal segmental glomerulosclerosis (FSGS) in children incorporates conservative management and immunosuppression regimens to control proteinuria and preserve kidney function. In long-term cohort studies in adults and children with primary FSGS, renal survival has been directly associated with degree of proteinuria control. This educational article reviews the current therapeutic approach toward children with primary FSGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.